Bioventus Inc. (BVS) Tops Q2 EPS by 12c; offers guidance

Bioventus Inc. (NASDAQ: BVS) reported Q2 EPS of $0.19, $0.12 better than the analyst estimate of $0.07. Revenue for the quarter came in at $151.22 million versus the consensus estimate of $137.6 million.

GUIDANCE:

Bioventus Inc. sees FY2024 EPS of $0.36-$0.42, versus the consensus of $0.28. Bioventus Inc. sees FY2024 revenue of $557-567 million, versus the consensus of $542.8 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• Morgan Stanley cuts China property forecasts on deeper price drops